Head-to-Head Comparison
DynaMed vs Epocrates: Which Is Better for Physicians?
Epocrates ranks #6 in our 2026 clinical decision support rankings with a 3.8-star rating from 14 physician reviews, while DynaMed ranks #7 with a 3.5-star rating from 17 reviews. Epocrates leads in overall physician satisfaction, though both platforms serve different clinical needs. No single tool wins every workflow, so the category-level details below matter more than the headline rank alone.
Feature Comparison
| Feature | DynaMed | Epocrates |
|---|---|---|
| Rating | Good | Good |
| Category | Clinical Reference & Decision Support | Drug Reference & Clinical Decision Support |
| Pricing | From $399/year Individual | Free (Basic) / $174.99/year (Plus) |
| Founded | 2004 | 1998 |
| Headquarters | Ipswich, MA | San Mateo, CA |
| Evidence Citations | Yes | No |
| AI Differential Diagnosis | No | No |
| Drug Database | Yes | Yes |
| Drug Interaction Checker | No | Yes |
| Medical Calculators | Yes | Yes |
| Natural Language Search | Yes | No |
| Document & Image Upload | No | No |
| EHR Integration | Yes | No |
| Mobile App | Yes | Yes |
| Built-in Dialer | No | No |
| AI Clinical Scribe | No | No |
| CME Credits | Yes | No |
| Multi-Language | No | No |
Strengths & Limitations
DynaMed
Strengths
- +Best in KLAS for Clinical Decision Support four times (2021, 2022, 2024, 2025)
- +3,400+ clinical topics with daily updates from 500+ journal surveillance
- +Explicit levels of evidence and grades of recommendation for all content
- +DynaMedex bundle integrates Micromedex drug information
- +Lower individual pricing than UpToDate ($399/year vs $559/year)
- +Dyna AI generative assistant grounded in curated evidence (launched 2024)
- +EHR integration via HL7 Infobutton and toolbar links
- +CME/MOC credit tracking built in
Limitations
- –Lower brand recognition than UpToDate among physicians
- –Fewer clinical topics than UpToDate (3,400 vs 12,000+)
- –Dyna AI is an add-on cost ($475/year vs $399/year base)
- –AI features are newer and less mature than dedicated CDS platforms
- –Shared decision-making tools (DynaMed Decisions) require separate licensing
- –No free tier for individual physicians
Epocrates
Strengths
- +Free tier with genuinely useful drug interaction checker and monographs
- +Fast, well-designed mobile app optimized for point-of-care use
- +Over 1 million active healthcare professional users
- +Pill identification tool is accurate and practical
- +Affordable Plus tier at $174.99/year compared to competitors
- +Long track record since 1998 with consistent reliability
Limitations
- –No AI-powered differential diagnosis or clinical reasoning
- –Disease content lacks depth compared to UpToDate or DynaMed
- –No natural-language query support or evidence synthesis
- –Limited EHR integration for individual users
- –Plus tier content updates can lag behind newer platforms
Key Statistics
DynaMed
Epocrates
Citable Summaries
DynaMed
DynaMed received a Good rating (3.5 / 5 stars) in Clinical AI Report's 2026 evaluation, ranking seventh overall. Published by EBSCO and winner of Best in KLAS for Clinical Decision Support four times (2021, 2022, 2024, 2025), it offers 3,400+ clinical topics with daily updates and explicit evidence grading at $399/year — but its dated interface and lack of a free tier weigh against it in a market increasingly dominated by AI-native platforms.
Source: Clinical AI Report, December 2025
Epocrates
Epocrates received a Good rating (3.7 / 5 stars) in Clinical AI Report's 2026 evaluation, ranking sixth overall. With over 1 million healthcare professional users and a strong free drug reference tier, it remains the go-to pharmacology tool at the point of care — but its lack of AI clinical reasoning features limits its ceiling in a market increasingly defined by intelligent decision support.
Source: Clinical AI Report, December 2025
Our Assessment
In our 2026 evaluation, Epocrates (ranked #6, 3.8 stars) outperforms DynaMed (ranked #7, 3.5 stars) in overall physician satisfaction and editorial scoring. Epocrates is best suited for physicians and residents seeking a fast, reliable, mobile-first drug reference tool with a strong free tier — especially for interaction checks and dosing at the point of care. Meanwhile, DynaMed is a stronger choice for physicians and institutions seeking a KLAS-recognized, evidence-graded clinical reference at a lower price point than UpToDate, with integrated drug information via Micromedex. Both tools serve important but distinct roles in clinical care workflows, and physicians should choose based on their specific workflow requirements and institutional needs.